impower133: is there finally a new standard of care for extensive stage sclc? (bmic-064)
Published 5 years ago • 427 plays • Length 7:19Download video MP4
Download video MP3
Similar videos
-
3:08
impower133 and caspian trials for extensive stage sclc
-
5:06
impower133 in sclc
-
6:33
a win for small–cell lung cancer: impower 133
-
8:11
first-line immunotherapy: impower133 regimen
-
6:32
the caspian versus impower133 regimen
-
5:23
atezolizumab carboplatin/etoposide for extensive-stage small cell lung cancer: impower133 update
-
7:20
small-cell lung cancer: the impower133 and caspian trials
-
4:40
emerging therapies for extensive stage sclc and caspian trial
-
4:17
how does lung cancer affect the body?
-
5:10
the spectrum of outcomes for small cell lung cancer
-
5:53
targeted therapy in non-small cell lung cancer
-
4:08
is there a place for maintenance therapy in extensive stage sclc?
-
1:50
impower133: atezolizumab, carboplatin plus etoposide for sclc
-
0:17
oncologists have a new weapon in their arsenal to attack extensive-stage small cell lung cancer.
-
3:30
immunotherapy treatments for non-small cell lung cancer (nsclc)
-
5:07
recent progress in the treatment of sclc
-
4:06
imdelltra: new fda-approved treatment for extensive-stage small cell lung cancer | 2024 update
-
5:22
chemoimmunotherapy for es sclc: impower133 trial
-
4:23
treatment approach in limited- and extensive-stage sclc
-
1:50
small cell lung cancer: interpreting data from impower133
-
3:13
treatment and management of small cell lung cancer (sclc)